Litcius/Paper detail

Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial

Richard M. Bergenstal, Ruth S. Weinstock, Chantal Mathieu, Yukiko Onishi, Vishali Vijayanagaram, Michelle L. Katz, Molly C. Carr, Annette M. Chang

2024The Lancet44 citationsDOI

Topics & Concepts

Insulin degludecMedicineInsulinBasal insulinDiabetes mellitusType 2 diabetesInternal medicineEndocrinologyDiabetes Management and ResearchDiabetes and associated disordersHyperglycemia and glycemic control in critically ill and hospitalized patients
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial | Litcius